【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the World Market for Cancer-Treating Drugs
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who is this Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Cancer Treatments
2.1 The Physiology of Cancer – Causes and Effects
2.1.1 Uncontrolled Growth
2.1.2 Dedifferentiation
2.1.3 Invasiveness and Metastasis
2.1.4 Causes of Cancer
2.2 The Incidence and Prevalence of Cancer – Trends in the World
2.2.1 Incidence
2.2.2 Mortality
2.2.3 Survival – Improving Odds
2.2.3.1 The Developed World
2.2.3.2 The Developing World – More Must Be Done
2.3 Treating Tumours – How Can We Fight Back?
2.3.1 Chemotherapy – The Traditional Treatment
2.3.2 Hormone Therapies
2.3.3 Immunotherapy – A Magic Bullet?
2.3.3.1 Monoclonal Antibodies (mAbs)
2.3.3.2 Cancer Vaccines
2.3.3.3 Non-Specific Immunotherapies
2.3.4 Targeted Therapies
2.3.5 Differentiating Agents
3. The World Anti-Cancer Drug Market, 2014-2024
3.1 Global Anti-Cancer Drugs Market Forecast, 2014-2024
3.2 The Domination of Immunotherapies in 2013
3.3 The Immunotherapy Anti-Cancer Drugs Market Forecast, 2014-2024 – The Fastest Growing Segment
3.4 The Chemotherapy Anti-Cancer Drugs Market Forecast, 2014-2024
3.5 The Targeted Therapy Anti-Cancer Drugs Market Forecast, 2014-2024 – A Move towards Personalisation
3.6 The Hormone Therapy Anti-Cancer Drugs Market Forecast, 2014-2024
4. Leading National Markets, 2014-2024
4.1 Anti-Cancer Drugs – Leading Markets, 2013
4.2 The US Anti-Cancer Drugs Market, 2014-2024 – Continued Leadership or Terminal Decline?
4.2.1 The US Anti-Cancer Drugs Market, 2013
4.2.2 The US Anti-Cancer Drugs Market Forecast – A Matured Approach
4.2.3 The Regulatory Effect on the US Market
4.3 The Japanese Anti-Cancer Drug Market, 2014-2024 – Still Steady?
4.4 The EU5 Anti-Cancer Drugs Market, 2014-2024 – Rivalling the US in Importance
4.5 The BRIC Countries Anti-Cancer Drugs Market, 2014-2024 – Awakening Sleeping Giants?
4.5.1 The Brazilian Anti-Cancer Drugs Market, 2014-2024 – Expansion of the Middle Class
4.5.2 The Russian Anti-Cancer Drugs Market, 2014-2024 – Rising Cancer Rates Stimulate Revenue Increases
4.5.3 The Indian Anti-Cancer Drugs Market, 2014-2024 – Lucrative Opportunity for Growth
4.5.4 The Chinese Anti-Cancer Drugs Market, 2014-2024 – Can it Fulfil its Potential?
5. The Top 25 Anti-Cancer Drugs, 2014-2024
5.1 Avastin (Roche) – The World Market Leader
5.1.1 Avastin Revenue, 2010-2013 – Mixed Growth
5.1.2 Avastin Revenue Forecast – Still No.1?
5.2 Herceptin (Roche) – The Looming Impact of Patent Expiry
5.2.1 Herceptin Revenue, 2010-2013 – Still Rising
5.2.2 Herceptin Revenue Forecast – Generic Erosion
5.3 Rituxan/MabThera (Roche) – Slowing Growth
5.3.1 Rituxan Revenue, 2010-2013 – Still Strong
5.3.2 Rituxan Revenue Forecast – Heading for a Decline
5.4 Gleevec/Glivec (Novartis) – The Maturation of a Blockbuster
5.4.1 Glivec Revenue, 2010-2013
5.4.2 Glivec Revenue Forecast – What Does the Future Hold?
5.5 Revlimid (Celgene) – Celgene’s Top Revenue Generator
5.5.1 Revlimid Revenue, 2010-2013 – Still on the Rise
5.5.2 Revlimid Revenue Forecast – A Long Term Leader?
5.6 Alimta (Eli Lilly) – A Slow Decline?
5.6.1 Alimta Revenue, 2010-2013
5.6.2 Alimta Revenue Forecast– Revenue Erosion Looming
5.7 Velcade (J&J/Takeda) – Rising Steadily
5.7.1 Velcade Revenue, 2010-2013
5.7.2 Velcade Revenue Forecast – A Dependable Sales Generator
5.8 Erbitux (Bristol-Myers Squibb/ Merck KGaA) – Facing Tough Competition
5.8.1 Erbitux Revenue, 2010-2013
5.8.2 Erbitux Revenue Forecast – No More Growth?
5.9 Gardasil (Merck & Co) – The Rise of Preventions
5.9.1 Gardasil Revenue, 2010-2013
5.9.2 Gardasil Revenue Forecast – Still Growing Strong
5.10 Zytiga (Johnson & Johnson)
5.10.1 Zytiga Revenue, 2010-2013 – The Rise of a New Drug
5.10.2 Zytiga Revenue Forecast
5.11 Xeloda (Roche) – Patent Exclusivity and the Future
5.11.1 Xeloda Revenue, 2010-2013 – The Impact of Combination Therapies
5.11.2 Xeloda Revenue Forecast – A Slippery Slope
5.12 Tarceva (Roche)
5.12.1 Tarceva Revenue, 2010-2013 – No Clear Pattern
5.12.2 Tarceva Revenue Forecast
5.13 Afinitor (Novartis) – A Targeted Approach
5.13.1 Afinitor Revenue, 2010-2013 – Growing Fast
5.13.2 Afinitor Revenue Forecast
5.14 Sprycel (Bristol-Myers Squibb)
5.14.1 Sprycel Revenue, 2010-2013
5.14.2 Sprycel Revenue Forecast – How Long Will the Growth Last?
5.15 Tasigna (Novartis) – Moving on Up
5.15.1 Tasigna Revenue, 2010-2013
5.15.2 Tasigna Revenue Forecast – A Multi-Billion Dollar Product?
5.16 Sutent (Pfizer)
5.16.1 Sutent Revenue, 2010-2013
5.16.2 Sutent Revenue Forecast – No More Growth
5.17 Nexavar (Bayer/Onyx Pharmaceuticals)
5.17.1 Nexavar Revenue, 2010-2013 – The Effect of Regional Sales
5.17.2 Nexavar Revenue Forecast – A Promising Start to the Decade
5.18 Xgeva (Amgen)
5.18.1 Xgeva Revenue, 2010-2013 – The Impact of New Indications
5.18.2 Xgeva Revenue Forecast
5.19 Zoladex (AstraZeneca)
5.19.1 Zoladex Revenue, 2010-2013
5.19.2 Zoladex Revenue Forecast
5.20 Yervoy (Bristol-Myers Squibb) – Starting to Make its Mark
5.20.1 Yervoy Revenue, 2011-2013
5.20.2 Yervoy Revenue Forecast – Will it Keep Growing?
5.21 Vidaza (Celgene) – What Growth Potential?
5.21.1 Vidaza Revenue, 2010-2013
5.21.2 Vidaza Revenue Forecast – Generic Impact
5.22 Treanda (Teva Pharmaceuticals)
5.22.1 Treanda Revenue, 2010-2013
5.22.2 Treanda Revenue Forecast – Stalled Growth?
5.23 Temodar/Temodal (Merck & Co.) – Falling off the Cliff?
5.23.1 Temodar/Temodal Revenue, 2010-2013
5.23.2 Temodar/Temodal Revenue Forecast
5.24 Faslodex (AstraZeneca) – The Counterpart to Zoladex
5.24.1 Faslodex Revenue, 2010-2013
5.24.2 Faslodex Revenue Forecast
5.25 Abraxane (Celgene) – Beginning the Climb
5.25.1 Abraxane Revenue, 2012-2013
5.25.2 Abraxane Revenue Forecast
6. Drugs Approved in 2013-2014: Potential Future Blockbusters
6.1 Approved Treatments in 2014
6.1.1 Beleodaq (Topotarget/Spectrum Pharmaceuticals)
6.1.1.1 Market Potential
6.1.2 Zykadia (Novartis) – The Rise of Kinase Inhibitors
6.1.2.1 Market Potential
6.1.3 Cyramza (Eli Lilly) – A Breakthrough for Gastric Cancer?
6.1.3.1 Market Potential
6.2 Approved Treatments in 2013
6.2.1 Imbruvica (Pharmacyclics)
6.2.1.1 Market Potential
6.2.2 Gazyva (Roche) – The First Breakthrough Therapy
6.2.2.1 Market Potential
6.2.3 Gilotrif (Boehringer Ingelheim)
6.2.3.1 Market Potential
6.2.4 Mekinist (GSK) – A First-in-Class Treatment for Melanoma
6.2.4.1 Market Potential
6.2.5 Tafinlar (GSK) – A Partner for Mekinist
6.2.5.1 Market Potential
6.2.6 Kadycla (Roche) – A Future Star
6.2.6.1 Market Potential – A Replacement for Herceptin?
6.2.7 Pomalyst (Celgene)
6.2.7.1 Market Potential
6.3 Drugs Approved in 2012 – How They’re Doing Now
6.3.1 Afinitor (Novartis) – Already a Blockbuster
6.3.1.1 Market Potential
6.3.2 Bosulif (Pfizer) – How Will it Perform?
6.3.2.1 Market Potential
6.3.3 Cometriq (Exelixis)
6.3.3.1 Market Potential
6.3.4 Erivedge (Roche) – Will It Become a Blockbuster?
6.3.4.1 Market Potential
6.3.5 Iclusig (Ariad)
6.3.5.1 Market Potential – Wider Uses?
6.3.6 Inlyta (Pfizer) – A Good Second-Line Option?
6.3.6.1 Market Potential
6.3.7 Kyprolis (Amgen)
6.3.7.1 Market Potential
6.3.8 Marqibo (Talon) – Will Its Revenue Grow?
6.3.8.1 Market Potential
6.3.9 Perjeta (Roche) – Joining the HER2 Family
6.3.9.1 Market Potential
6.3.10 Stivarga (Bayer)
6.3.10.1 Market Potential
6.3.11 Synribo (Teva)
6.3.11.1 Market Potential
6.3.12 Votrient (GSK)
6.3.12.1 Market Potential
6.3.13 Xtandi (Medivation) – Quickly Becoming a Popular Choice
6.3.13.1 Market Potential
6.3.14 Zaltrap (Sanofi)
6.3.14.1 Market Potential
7. Leading Companies for Cancer Treatments, 2014
7.1 Anti-Cancer Drug Market Dominated by Seven Companies
7.2 Roche – Leader of the Pack
7.2.1 Oncology Pipeline – Investment in the Future
7.2.2 Roche’s Future Direction in Cancer Treatment
7.3 Novartis – Closing the Gap on Roche
7.3.1 Oncology R&D Pipeline – What’s the Potential?
7.3.2 Future Directions for Novartis
7.4 Celgene – Pressing Need to Diversify?
7.4.1Celgene’s Oncology Pipeline – Safeguarding the Future
7.4.2 Future Directions for Celgene
7.5 Eli Lilly – Reliant on Alimta
7.5.1 Oncology R&D Pipeline – What Potential Exists?
7.5.2 The Future Direction of Eli Lilly
7.6 AstraZeneca – Climbing up the Ladder
7.6.1 Oncology Pipeline – Showing Promise
7.6.2 The Future Direction of AstraZeneca
7.7 Bristol-Myers Squibb
7.7.1 Oncology R&D Pipeline – What Potential Exists?
7.7.2 Future Direction of BMS
7.8 Merck & Co. – Prominent in Vaccines
7.8.1 Oncology Pipeline – Greater Focus on Cancer
7.8.2 The Future Direction of Merck
8. R&D Pipelines for Cancer Treatment
8.1 Breast Cancer Drugs Under Development
8.1.1 Neratinib (Puma Pharmaceuticals)
8.1.2 Palbociclib (Pfizer)
8.1.3 Veliparib (Abbvie)
8.1.4 NeuVax (Galena Biopharma)
8.1.5 Entinostat (Syndax)
8.2 Prostate Cancer Drugs Under Development
8.2.1 OMD-201 (Orion)
8.2.2 Tasquinimod (Active Biotech)
8.2.3 EMD-525797 (EMD Serono)
8.2.4 PROSTVAC (Bavarian Nordic)
8.3 Lung Cancer Drugs Under Development
8.3.1 Tecemotide (Merck Serono)
8.3.2 RG7446 (Roche)
8.3.3 Nivolumab (Bristol-Myers Squibb)
8.3.4 MEDI4736 (AstraZeneca)
8.3.5 TG4010 (Transgene)
8.4 Colorectal Cancer Drugs Under Development
8.4.1 Imprime PGG (Biothera)
8.4.2 Xilonix (Xbiotech)
8.4.3 TAS-102 (Taiho Pharmaceuticals)
8.4.4 HA-Irinotecan (Alchemia)
8.4.5 Aptocine (Light Sciences Oncology)
8.5 Cervical Cancer Drugs Under Development
8.5.1 ADXS-HPV (Advaxis)
8.5.2 V503 (Merck & Co.)
8.5.3 VGX-3100 (Inovio Pharmaceuticals)
8.6 Stomach Cancer Drugs Under Development
8.6.1 Rilotumumab (Amgen)
8.6.2 Onartuzumab (Roche)
8.6.3 Apatinib (Jiangsu Hengrui Medicine)
8.7 Liver Cancer Drugs Under Development
8.7.1 Tivantinib (ArQule)
8.7.2 Lenvatinib (Eisai Co.)
8.7.3 Pexa-Vec9 (Jennerex Biotherapeutics)
8.7.4 Brivanib (Bristol-Myers Squibb)
8.7.5 Muparfostat (Progen Pharmaceuticals)
8.8 Ovarian Cancer Drugs Under Development
8.8.1 Farletuzumab (Eisai)
8.8.2 Niraparib (TESARO)
8.8.3 Trebananib (Amgen)
8.8.4 SG2000 (Spirogen)
8.9 Bladder Cancer Drugs Under Development
8.9.1 Vesimune (Telormedix)
8.9.2 HS-410 (Heat Biologics)
8.9.3 EOquin (Allergan)
8.10 Non-Hodgkin’s Lymphoma Drugs Under Development
8.10.1 Idelalisib (Gilead)
8.10.2 IPI-145 (Infinity Pharmaceuticals)
8.10.3 ABT-199 (AbbVie)
8.10.4 GS-9973 (Gilead)
8.11 Leukaemia Drugs Under Development
8.11.1 Dinaciclib (Merck)
8.11.2 Sapacitabine (Cyclacel Pharmaceuticals)
8.11.3 Vosaroxin (Sunesis)
8.12 Kidney Cancer Drugs Under Development
8.12.1 IMA901 (Immatics)
8.12.2 ASG-003 (Argos Therapeutics)
8.12.3 Nilovumab (Bristol-Myers Squibb)
8.12.4 TRC105 (Tracon Pharmaceuticals)
8.13 Pancreatic Cancer Drugs Under Development
8.13.1 Algenpantucel-L (NewLink Genetics)
8.13.2 MM-398 (Merrimack)
8.13.3 MK-0752 (Merck & Co.)
9. Qualitative Analysis of the Anti-Cancer Drug Market 2014-2024
9.1 SWOT Analysis of the Anti-Cancer Drugs Market
9.1.1 Strengths of the Market
9.1.1.1 The Rising Incidence of Cancer
9.1.1.2 Ample Treatment Options Available
9.1.2 Weaknesses
9.1.2.1 The Challenges of Drug Development
9.1.2.2 The Complex Nature of Cancer
9.1.3 Opportunities in the Anti-Cancer Drugs Market
9.1.3.1 The Advancement of Research
9.1.3.2 A Shift Towards Personalisation
9.1.4 Threats Facing the Anti-Cancer Drugs Market
9.1.4.1 The Threat of Regulation
9.2 STEP Analysis of the Anti-Cancer Drugs Market
9.2.1 Social Factors: The Cost of Living Longer
9.2.2 Technological Developments: Making the Market Move Forward
9.2.3 Economic Pressure: Treatment’s Hefty Price Tag
9.2.4 Political Issues: Governmental Involvement in Treatment
10. Research Interviews
10.1 Interview with Mr Thomas Felzmann, CEO, Activartis Biotech GmbH, Vienna, Austria
10.1.1 Activartis Biotech and AV0113
10.2 Interview with Professor Philip Rudland, Chair of Biochemistry at the University of Liverpool
10.2.1 Identifying Markers in Cancer Cells
10.2.2 The Importance of Protein Expression
10.2.3. The Advancement of Diagnostics
10.2.4 The Future of the Anti-Cancer Drug Market
10.3 Interview with Dr Sidong Huang, Assistant Professor of Biochemistry at McGill University
10.3.1 On His Research Interests and their Utility in Anti-Cancer Drug Development
10.3.2 On the Evaluation of New Targets for Anti-Cancer Drugs
10.3.3 On Drug Resistance and Targeted Therapies
10.3.4 On the Future of Traditional Chemotherapy
10.3.5 On Future Developments in the Anti-Cancer Field
10.4 Interview with Dr Neil Butt, Director, Antitope Ltd.
10.4.1 On Immunogenicity in Therapeutic Proteins
10.4.2 On Antitope’s Technologies to Assess and Reduce Immunogenicity
10.4.3 On an Alternative Way of Reducing Immunogenicity
10.4.4 On Biosimilars
10.4.5 On Future Developments in that Field
11. Conclusions of the Study
11.1 The Top 25 Drugs in the Cancer Treatment Market
11.2 Immunotherapies – The Future of the Market
11.3 Patent Expiries and the Impact of Biosimilars
11.4 The US – Still the Largest National Market
11.5 China and Brazil Will Lead the Emerging Markets
11.6 Treatment – It’s Personal
11.7 The Anti-Cancer Drug Pipeline Remains Strong
11.8 Concluding Remarks
【レポート販売概要】
■ タイトル：世界の抗がん剤市場：治療法、研究開発動向及び市場予測■ 英文：ANTI-CANCER DRUGS INDUSTRY AND MARKET: THERAPIES, R&D AND FORECASTS 2014-2024
■ 発行日：2014年8月
■ 調査会社：visiongain
■ 商品コード：VISG409045
■ 調査対象地域：グローバル
- 腐りやすい食品輸送の世界市場2016-2020About Perishable Goods Transportation Perishable goods transportation involves the transportation of temperature-sensitive goods. It is an integrated component of cold chain logistics and helps in the management and control of the flow of the cold chain supply process. A rise in international trade has increased the need for the transportation of perishable products from producers to end-users in …
- 世界のヘアケア製品市場動向：企業M&A（2014年5月）Synopsis The report provides a review of the mergers and acquisitions (M&As), partnering deals, and agreements entered into by companies active in the global haircare market during May 2014. Summary Using this report, dealmakers will effectively gain an insight into deal activity of the global haircare market throughout the month. Additionally, the report provides an overview of all the partnering …
- 放射免疫測定（RIA）の世界市場：放射免疫測定試薬、放射免疫測定キット、放射免疫測定装置This report on the global radioimmunoassay market is analysed and segmented on the basis of type, application, end user, and region. It analyzes the competitive developments, such as alliance, joint venture, and merger & acquisition, in the global radioimmunoassay market. This market is also analyzed with an explicit focus on the high-growth applications and fastest-growing market segments. The te …
- 北米のウォーターヒーター市場About the Water Heater Market in North America The demand for heating appliances is considerably high in most North American countries owing to the cold weather conditions prevailing in the region. Also, in recent years, it has been noted that the winter season in the region is getting affected by El Niño, which brings in unpredictable weather, flooding, and harsh wet winter. This unpredictable ch …
- アドバンスド・モーション・コントローラの世界市場About Advanced Motion Controller An advanced motion controller is a device which is used to input control signals to a driver that operates a motor, based on the motion control requirement of the operation. There are various types of advanced motion controllers such as stand-alone controller, computer-based controller, PLC-based controller, and servo-based controller. TechNavio's analysts forecast …
- 世界の光学パターン付きウエハ検査装置市場動向（2014-2018）Abstract About BI and Analytics Platforms Optical patterned wafer inspection equipment is used to detect defects that occur during the semiconductor manufacturing processes. The increasing complexity of semiconductor manufacturinge due to new design rules and processes has increased the density of defects in the semiconductor wafers. This in turn can ruin an entire wafer rather than just a die. Th …
- 気流管理の世界市場予測（～2023年）：ブランキングパネル、グロメット、コンテインメント、空気注入キットThe airflow management market is projected to grow from USD 475.2 Million in 2017 to reach USD 807.3 Million by 2023, at a CAGR of 9.24% between 2017 and 2023. Factors such as increasing number of data centers worldwide and improving cooling efficiency and thermal management in data centers are driving the growth of the airflow management market. The airflow management market has been segmented on …
- 医薬品のブラジル市場見通し2016-2026Medicine Sales in Brazil – How to Find Trends, Opportunities and Forecasted Revenues Do you want to assess Brazil’s pharmaceutical market from 2016? If so, visiongain’s new report gives you revenue forecasts, helping your research and analysis. That study’s purpose is to show opportunities, trends and sales predictions to 2026. Brazil can satisfy expectations for wider healthcare coverage and rapi …
- 発電用地熱掘削の世界市場2019-2023Global Geothermal Drilling Market for Power Generation 2019-2023: About this market Technavio’s geothermal drilling market for power generation market analysis considers power generation from both binary plants and steam plants. Our analysis also considers the geothermal drilling for power generation in APAC, America, and EMEA. In 2018, the binary-plant segment had a significant share, and this tr …
- ガソリンスタンド装置の世界市場2017-2021About Gas Station EquipmentA gas station is a facility where fuels like petrol, diesel, LNG, and CNG are sold. Gas station equipment include fuel dispensers, fuel tanks, fuel pumps, filters, and others. Some gas stations also have convenience stores where people can buy food, beverages, and other items. Technavio’s analysts forecast the global gas station equipment market to grow at a CAGR of 5.56 …
- 天然・オーガニックタンポンの世界市場2016-2020About Natural and Organic Tampons An organic tampon is made of organic cotton and is free of any chemicals. It comes with an applicator that is made of bioplastic material. Natural and organic tampons come under Class II of medical devices under FDA and CE regulations in the US and Europe, and are manufactured under strong guidelines by the vendors in the particular region. These products are stri …
- セラミック衛生陶器の世界市場：便器、洗面台、水槽などThe growth in the real estate industry together with the changing preferences of the consumers towards hygienic products is driving the market for ceramic sanitary ware. The ceramic sanitary ware products are required in public, residential and commercial areas. Asia-Pacific accounts for a major share in the ceramic sanitary ware market. The booming construction industry in the region gives rise t …
- ホーム・エネルギー管理システム（HEMS）の世界市場：制御デバイス、ディスプレイ、通信デバイスThe global Home Energy Management System Market is expected to grow from USD 864.2 Million in 2015 to USD 3.15 Billion by 2022, at a CAGR of 18.36% between 2016 and 2022. The HEMS market is expected to grow substantially owing to factors such as increasing real-time energy conservation approach, convenience of cloud computing and data analytics, and increased device interconnectivity. Lighting con …
- 世界のイスラム金融市場動向（2012-2016）TechNavio's analysts forecast the Global Islamic Banking market to grow at a CAGR of 21.43 percent over the period 2012-2016. One of the key factors contributing to this market growth is the tremendous growth in the Global Halal Food industry. The Global Islamic Banking market has also been witnessing the development of sophisticated regulatory framework. However, the intense competition from conv …
- 世界の血液凝固検査用試薬及び装置（医療機器）市場This unique report from Venture Planning Group provides sales and market share estimates for major suppliers of coagulation reagents and instruments by country. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and busines …
